Cargando…

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

T cells are involved in control of SARS-CoV-2 infection. To establish the patterns of immunodominance of different SARS-CoV-2 antigens and precisely measure virus-specific CD4(+) and CD8(+) T cells, we study epitope-specific T cell responses of 99 convalescent coronavirus disease 2019 (COVID-19) cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarke, Alison, Sidney, John, Kidd, Conner K., Dan, Jennifer M., Ramirez, Sydney I., Yu, Esther Dawen, Mateus, Jose, da Silva Antunes, Ricardo, Moore, Erin, Rubiro, Paul, Methot, Nils, Phillips, Elizabeth, Mallal, Simon, Frazier, April, Rawlings, Stephen A., Greenbaum, Jason A., Peters, Bjoern, Smith, Davey M., Crotty, Shane, Weiskopf, Daniela, Grifoni, Alba, Sette, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837622/
https://www.ncbi.nlm.nih.gov/pubmed/33521695
http://dx.doi.org/10.1016/j.xcrm.2021.100204
_version_ 1783642992130654208
author Tarke, Alison
Sidney, John
Kidd, Conner K.
Dan, Jennifer M.
Ramirez, Sydney I.
Yu, Esther Dawen
Mateus, Jose
da Silva Antunes, Ricardo
Moore, Erin
Rubiro, Paul
Methot, Nils
Phillips, Elizabeth
Mallal, Simon
Frazier, April
Rawlings, Stephen A.
Greenbaum, Jason A.
Peters, Bjoern
Smith, Davey M.
Crotty, Shane
Weiskopf, Daniela
Grifoni, Alba
Sette, Alessandro
author_facet Tarke, Alison
Sidney, John
Kidd, Conner K.
Dan, Jennifer M.
Ramirez, Sydney I.
Yu, Esther Dawen
Mateus, Jose
da Silva Antunes, Ricardo
Moore, Erin
Rubiro, Paul
Methot, Nils
Phillips, Elizabeth
Mallal, Simon
Frazier, April
Rawlings, Stephen A.
Greenbaum, Jason A.
Peters, Bjoern
Smith, Davey M.
Crotty, Shane
Weiskopf, Daniela
Grifoni, Alba
Sette, Alessandro
author_sort Tarke, Alison
collection PubMed
description T cells are involved in control of SARS-CoV-2 infection. To establish the patterns of immunodominance of different SARS-CoV-2 antigens and precisely measure virus-specific CD4(+) and CD8(+) T cells, we study epitope-specific T cell responses of 99 convalescent coronavirus disease 2019 (COVID-19) cases. The SARS-CoV-2 proteome is probed using 1,925 peptides spanning the entire genome, ensuring an unbiased coverage of human leukocyte antigen (HLA) alleles for class II responses. For HLA class I, we study an additional 5,600 predicted binding epitopes for 28 prominent HLA class I alleles, accounting for wide global coverage. We identify several hundred HLA-restricted SARS-CoV-2-derived epitopes. Distinct patterns of immunodominance are observed, which differ for CD4(+) T cells, CD8(+) T cells, and antibodies. The class I and class II epitopes are combined into epitope megapools to facilitate identification and quantification of SARS-CoV-2-specific CD4(+) and CD8(+) T cells.
format Online
Article
Text
id pubmed-7837622
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78376222021-01-27 Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases Tarke, Alison Sidney, John Kidd, Conner K. Dan, Jennifer M. Ramirez, Sydney I. Yu, Esther Dawen Mateus, Jose da Silva Antunes, Ricardo Moore, Erin Rubiro, Paul Methot, Nils Phillips, Elizabeth Mallal, Simon Frazier, April Rawlings, Stephen A. Greenbaum, Jason A. Peters, Bjoern Smith, Davey M. Crotty, Shane Weiskopf, Daniela Grifoni, Alba Sette, Alessandro Cell Rep Med Article T cells are involved in control of SARS-CoV-2 infection. To establish the patterns of immunodominance of different SARS-CoV-2 antigens and precisely measure virus-specific CD4(+) and CD8(+) T cells, we study epitope-specific T cell responses of 99 convalescent coronavirus disease 2019 (COVID-19) cases. The SARS-CoV-2 proteome is probed using 1,925 peptides spanning the entire genome, ensuring an unbiased coverage of human leukocyte antigen (HLA) alleles for class II responses. For HLA class I, we study an additional 5,600 predicted binding epitopes for 28 prominent HLA class I alleles, accounting for wide global coverage. We identify several hundred HLA-restricted SARS-CoV-2-derived epitopes. Distinct patterns of immunodominance are observed, which differ for CD4(+) T cells, CD8(+) T cells, and antibodies. The class I and class II epitopes are combined into epitope megapools to facilitate identification and quantification of SARS-CoV-2-specific CD4(+) and CD8(+) T cells. Elsevier 2021-01-26 /pmc/articles/PMC7837622/ /pubmed/33521695 http://dx.doi.org/10.1016/j.xcrm.2021.100204 Text en © 2021 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Tarke, Alison
Sidney, John
Kidd, Conner K.
Dan, Jennifer M.
Ramirez, Sydney I.
Yu, Esther Dawen
Mateus, Jose
da Silva Antunes, Ricardo
Moore, Erin
Rubiro, Paul
Methot, Nils
Phillips, Elizabeth
Mallal, Simon
Frazier, April
Rawlings, Stephen A.
Greenbaum, Jason A.
Peters, Bjoern
Smith, Davey M.
Crotty, Shane
Weiskopf, Daniela
Grifoni, Alba
Sette, Alessandro
Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
title Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
title_full Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
title_fullStr Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
title_full_unstemmed Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
title_short Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
title_sort comprehensive analysis of t cell immunodominance and immunoprevalence of sars-cov-2 epitopes in covid-19 cases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837622/
https://www.ncbi.nlm.nih.gov/pubmed/33521695
http://dx.doi.org/10.1016/j.xcrm.2021.100204
work_keys_str_mv AT tarkealison comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT sidneyjohn comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT kiddconnerk comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT danjenniferm comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT ramirezsydneyi comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT yuestherdawen comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT mateusjose comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT dasilvaantunesricardo comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT mooreerin comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT rubiropaul comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT methotnils comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT phillipselizabeth comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT mallalsimon comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT frazierapril comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT rawlingsstephena comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT greenbaumjasona comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT petersbjoern comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT smithdaveym comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT crottyshane comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT weiskopfdaniela comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT grifonialba comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases
AT settealessandro comprehensiveanalysisoftcellimmunodominanceandimmunoprevalenceofsarscov2epitopesincovid19cases